Marshall Wace’s AbbVie ABBV Stock Holding History

Marshall Wace’s Portfolio ABBV Stock Details ABBV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-188,300	Closed	-$29.2M	–	2387
2023 Q4	$29.2M	Buy	+188,300	New	+$27.5M	0.05%	369
2023 Q3	–	Sell	-72,700	Closed	-$9.79M	–	2129
2023 Q2	$9.79M	Buy	72,700 +66,500	+1,073%	+$9.75M	0.02%	736
2023 Q1	$988K	Buy	+6,200	New	+$948K	﹤0.01%	1816
2022 Q4	–	Sell	-7,600	Closed	-$1.02M	–	2873
2022 Q3	$1.02M	Buy	+7,600	New	+$1.09M	﹤0.01%	2395
2021 Q4	–	Sell	-300	Closed	-$32K	–	3808
2021 Q3	$32K	Buy	+300	New	+$34.3K	﹤0.01%	2948
2021 Q2	–	Sell	-15,900	Closed	-$1.72M	–	2594
2021 Q1	$1.72M	Buy	+15,900	New	+$1.7M	0.01%	1396

Other funds holding ABBV

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Marshall Wace's ABBV Position: Q1 2026 in Review

Marshall Wace reduced its AbbVie (ABBV) stake by 100% in Q1 2026, selling an estimated $144M and leaving 1,061 shares worth $231K. The position accounts for ﹤0.01% of the portfolio, ranked #2728.

Marshall Wace first reported a position in ABBV in Q3 2014 and has held it in 38 quarters since. The position peaked at $582M in Q3 2023. 4,077 funds tracked by Wall St. Rank hold ABBV as of Q1 2026.

Marshall Wace held 1,061 shares of AbbVie worth $231K as of Q1 2026.
Marshall Wace sold 648,939 AbbVie shares in Q1 2026, an estimated $144M.
AbbVie made up ﹤0.01% of Marshall Wace's portfolio in Q1 2026, its #2728 holding.
Marshall Wace first reported a position in AbbVie in Q3 2014 and has held it in 38 quarters since.
Marshall Wace's AbbVie position peaked at $582M in Q3 2023.
4,077 funds tracked by Wall St. Rank held AbbVie as of Q1 2026.

Based on Marshall Wace's 13F filing for Q1 2026, filed 15 May 2026.